252 related articles for article (PubMed ID: 17889118)
1. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies.
Anglicheau D; Legendre C; Thervet E
Transplant Proc; 2007 Sep; 39(7):2142-4. PubMed ID: 17889118
[TBL] [Abstract][Full Text] [Related]
2. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
Wang J
Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
5. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.
Masuda S; Inui K
Pharmacol Ther; 2006 Oct; 112(1):184-98. PubMed ID: 16759707
[TBL] [Abstract][Full Text] [Related]
6. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.
Ware N; MacPhee IA
Curr Opin Mol Ther; 2010 Jun; 12(3):270-83. PubMed ID: 20521216
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
Mendes J; Martinho A; Simoes O; Mota A; Breitenfeld L; Pais L
Transplant Proc; 2009 Apr; 41(3):840-2. PubMed ID: 19376366
[TBL] [Abstract][Full Text] [Related]
8. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.
Kniepeiss D; Renner W; Trummer O; Wagner D; Wasler A; Khoschsorur GA; Truschnig-Wilders M; Tscheliessnigg KH
Clin Transplant; 2011; 25(1):146-50. PubMed ID: 20041908
[TBL] [Abstract][Full Text] [Related]
9. Use of pharmacogenetics to optimize immunosuppressive therapy.
Macphee IA
Ther Drug Monit; 2010 Jun; 32(3):261-4. PubMed ID: 20431509
[TBL] [Abstract][Full Text] [Related]
10. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.
Mourad M; Wallemacq P; De Meyer M; Malaise J; De Pauw L; Eddour DC; Goffin E; Lerut J; Haufroid V
Transplantation; 2008 Apr; 85(7 Suppl):S19-24. PubMed ID: 18401258
[TBL] [Abstract][Full Text] [Related]
11. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms.
Li D; Gui R; Li J; Huang Z; Nie X
Transplant Proc; 2006 Nov; 38(9):2850-2. PubMed ID: 17112846
[TBL] [Abstract][Full Text] [Related]
13. Low tacrolimus dose requirements in renal transplant recipients in the omani population: implications for pharmacogenetics?
Mohsin N; Pakkyara A; Budruddin M; Obaid F; Kumar A; Malvathu S; Kalankara S; Amitabh A; Daar A
Transplant Proc; 2005 Sep; 37(7):2911-2. PubMed ID: 16213259
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
15. Genetic factors for individual administration of immunosuppressants in organ transplantation.
Yu SF; Wu LH; Zheng SS
Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):337-44. PubMed ID: 16911928
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.
Anglicheau D; Legendre C; Beaune P; Thervet E
Pharmacogenomics; 2007 Jul; 8(7):835-49. PubMed ID: 18240909
[TBL] [Abstract][Full Text] [Related]
17. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics in solid organ transplantation: current status and future directions.
de Jonge H; Kuypers DR
Transplant Rev (Orlando); 2008 Jan; 22(1):6-20. PubMed ID: 18631854
[TBL] [Abstract][Full Text] [Related]
19. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
Wallemacq P; Armstrong VW; Brunet M; Haufroid V; Holt DW; Johnston A; Kuypers D; Le Meur Y; Marquet P; Oellerich M; Thervet E; Toenshoff B; Undre N; Weber LT; Westley IS; Mourad M
Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
[TBL] [Abstract][Full Text] [Related]
20. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients.
Akbas SH; Bilgen T; Keser I; Tuncer M; Yucetin L; Tosun O; Gultekin M; Luleci G
Transplant Proc; 2006 Jun; 38(5):1290-2. PubMed ID: 16797284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]